Circio Holding ASA

Circio Holding ASA: Minutes from the annual general meeting 2025

Oslo, 5 June 2025: Circio Holding ASA (the "Company") held its annual general

meeting today, 5 June 2025, as a physical meeting at the Company's offices at

Universitetsgata 2, 0164 Oslo.

All resolutions were made in accordance with the proposals from the board of

directors and the nomination committee, including, but not limited to, approval

of the 2024 annual accounts and the approval of authorizations to the board of

directors.

The minutes from the annual general meeting are attached hereto and will also be

made available on the Company's website circio.com/investors/general

-meetings (https://www.circio.com/en/section/investors/general-meetings/).

This information is subject to disclosure requirements pursuant to Section 5-12

of the Norwegian Securities Trading Act.

For further information, please contact:

Erik Digman Wiklund, CEO

Phone: +47 413 33 536

Lubor Gaal, CFO

Phone: +34 683343811

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA

vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression

platform for novel DNA, RNA and viral therapeutics. The proprietary circVec

technology is based on a modular genetic cassette design for efficient

biogenesis of multifunctional circRNA inside cells, which can be deployed in

multiple therapeutic settings, including genetic medicine, cell therapy and

chronic disease. The circVec platform has demonstrated up to 15-fold enhanced

and more significantly more durable protein expression vs. classic mRNA vector

systems and has the potential to become a new gold-standard platform technology

for nucleic acid and viral therapeutics in the future. The circRNA R&D

activities are being conducted by the wholly owned subsidiary Circio AB based at

the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS

driver mutations. TG01 is currently being tested in two clinical trials: RAS

-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.

These studies are being run through academic and industry collaborative

networks, supported by prestigious research grants from Innovation Norway and

the Norwegian Research Council, creating read-outs and future optionality for

the program at low cost to Circio.

AI Terminal